Trump Puts Plan In Motion To Open The Strait Of Hormuz

🏀 Tune in wherever you are to catch every second of March Madness!

Facebook X InstagramNCAA, March Madness and The Road to Indianapolis are trademarks owned by the National Collegiate Athletic Association. All other licenses or trademarks are property of their respective holders.National Collegiate Athletic Association
700 W. Washington St.
Indianapolis, IN 46204You are receiving this email because you signed up to receive the NCAA.com promotional emails.Update Your Preferences or Unsubscribe | Privacy Policy | View as Webpage

Markets Brace for the Fed as Oil Jumps and Futures Dip

Good Morning From
THE WEALTHIEST INVESTOR

Elon’s biggest liability

Editor’s note: As Silicon Valley power players battle to achieve Artificial General Intelligence (“AGI”), a more powerful force threatens to stop AI’s progress dead in its tracks.

According to futurist Eric Fry from our corporate affiliate InvestorPlace, as this critical bottleneck comes to light, investors will witness a market-wide regime change, violently ejecting today’s winners and replacing them with a brand-new class of unexpected companies.

Eric is sharing the full list of companies he says to buy and sell as this $10 trillion market shock unfolds, which you can learn about below…

Dear Reader,

On the morning of August 12, 2024, I sat down in a recording studio in Baltimore and said something that sounded absurd to almost everyone in the room.

I declared that artificial general intelligence (“AGI”) — superhuman AI with its own version of free will — would emerge from Silicon Valley labs in 2026.

At the time, the expert consensus said we had until 2030.

Fast forward to today, and multiple reputable sources are confirming what I predicted: AGI is here.

This is, without question, the most significant technological development in human history.

And yet — here’s where I need you to pay very close attention — it may be the worst possible thing that could happen to your portfolio right now.

The market shock is the counterintuitive call nobody wants to hear — but that could save you from ruin…

AGI is the holy grail that Elon Musk, Mark Zuckerberg, and Sam Altman have spent hundreds of billions of dollars racing to achieve.

And now that it’s beginning to emerge… the Magnificent Seven stocks that funded that race are the last place you want your money.

I know how that sounds. But it wouldn’t be the first time one of my absurd calls became tomorrow’s reality.

In 2000, when the Internet boom was still booming — and companies like Cisco were growing revenues by 50% a year — I told my readers to get out of tech.

The crowd called it absurd. The charts called it absurd. The headlines called it absurd.

Then the crash came.

Tech stocks I said to sell fell 64% to 85%. Investors who didn’t listen watched years of gains evaporate almost overnight.

But the readers who followed my buyrecommendations into overlooked, asset-heavy companies?

They saw gains of 159%… 206%… 271%… even 1,004% — while everyone else was picking up the pieces.

Here’s exactly how my buy and sell calls looked, side by side:

That’s what happens when you get out in front of a regime change instead of being run over by it.

Join me at FutureProof 2026 by registering for free here.

I believe we are at that same inflection point right now, except…

This time around, the stakes are even higher…

Beginning April 24, a series of announcements out of the world’s most powerful AI companies will expose cracks in the AGI story that Wall Street is not prepared for.

First, the headlines will insist everything is fine.

Then the selling will start.

By the time the average investor figures out why the biggest names in the market are falling by as much as 50%, it will be too late to protect themselves — let alone position for what comes next.

That’s why I’m hosting FutureProof 2026 onWednesday, March 18, at 1 p.m. Eastern time— a free live event where I’ll release my complete Market Shock Profit Playbook, including 15 stock names and tickers I predict could receive an influx of $10 trillion in capital in the wake of the Market Shock.

The readers who acted on my dot-com calls didn’t wait until after the crash to do so.

Neither should you.

Grab your spot at FutureProof 2026 here — it’s free.

I’ll show you exactly which stocks to sell, which to buy, and where I believe the smart money is moving next.

The time to get futureproofed is now.

Sincerely,

Eric Fry
Futurist and Senior Analyst, InvestorPlace

You are receiving this e-mail because you are a subscriber to Chaikin Analytics content. To unsubscribe from special offers like this one, click here to unsubscribe.

Published by Chaikin Analytics, LLC.

You’re receiving this e-mail at pahovis@aol.com. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. – 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice.

© 2026 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com.

The Pentagon Can’t Replace This Metal

Unsubscribe

A message from our friends at i2i Marketing Group, LLC

The Military Budget Is Near $1T – This Sits at the Center

Ammunition. Missile systems. Night vision.

One metal runs through all of it.

And most of the world’s supply sits in the hands of geopolitical rivals like China and Russia.

America is on the look out for its own sources.

Defense budgets are rising. Export restrictions have tightened. Governments are building their own reserves.

When military supply chains depend on foreign rivals, secure North American deposits can suddenly become a strategic advantage.

That’s why a high-grade deposit just miles from the U.S. border is starting to draw attention.

Drilling is underway and somehow the market hasn’t fully caught up yet.

Discover the company advancing this strategic deposit >

Exclusive News

D-Wave Keeps Delivering Good News—So Why Is It Falling?

Author: Nathan Reiff. Originally Published: 3/11/2026.

Key Points

D-Wave Quantum shares remain down about a third year-to-date despite numerous technological and business successes.
The company’s bookings and revenue have climbed rapidly alongside gross margin, but operating expenses are also climbing, keeping profitability distant for now.
With a major new Fortune 100 client and other sales momentum, D-Wave may test investor patience while it works to bring its financials in line with its valuation.
Special Report: Two AI Stocks Getting Quiet Attention (From Darwin)

A longtime speculative play in the risky and emergent quantum computing industry, D-Wave Quantum Inc. (NYSE: QBTS) looks poised to separate true quantum believers from investors who rode its roughly 168% surge in 2025. Despite that rally, D-Wave shares have mostly traded down or flat through 2026; QBTS is down nearly a third year-to-date.

Some reasons for the pullback are obvious: the company missed analyst expectationson both earnings and revenue in the most recent quarter, and rivals like IonQ Inc. (NYSE: IONQ) may be quietly outperforming on some metrics.

Altucher: My #1 FREE Stock Pick is NYSE: (___) (Ad)

In this short 3-min. video, legendary investor James Altucher reveals the name and ticker symbol of a company he believes will skyrocket as soon as March 26th…

That would make it the biggest IPO in history!Click here to check it out before it’s too late.

Still, several positive developments that might have reversed the downtrend have emerged in recent months.

Specifically, strong bookings growth, a high-profile new deal, and a shift to a two-pronged technological approach have so far failed to right the QBTS ship.

D-Wave’s Rally, Cut Short in October, Waits for a Reason to Relaunch

To understand D-Wave’s current position, it helps to go back to October 2025, when the selloff began. After reaching about $45 per share in mid‑October, QBTS plunged to less than half that level in the following weeks, before a modest recovery into year‑end. There wasn’t a clear fundamental catalyst for the reversal; it may have been profit‑taking or a growing concern that the hype had outpaced D‑Wave’s tangible progress at the time.

If that concern was driving the selloff, the rally could resume once the company delivers evidence that investors have reasons to be excited beyond general market enthusiasm. That evidence has been building in some respects: well over $30 million in bookings so far in 2026, a 265% increase in gross profit for full‑year 2025, and a gross margin approaching 83% last year.

Financials and Tech-Side Potential May Still Be Mismatched

D-Wave’s financial improvements are notable, but two metrics may keep many investors unconvinced that a $45-per-share valuation is justified. First, revenue remains small—about $25 million in 2025—for a company with a roughly $7 billion market capitalization, even though revenue nearly tripled year‑over‑year. Second, operating expenses rose 46% in 2025 to roughly $121 million.

Revenue is growing faster than expenses, and strong bookings and margins are constructive, but the company still appears some distance from reporting a break‑even or profitable quarter. Valuation is another hurdle: D‑Wave’s price/sales ratio is extremely high (about 286.5) while book value is roughly $2.30 per share. Even with a newly announced agreement with a Fortune 100 company, investors may reasonably question D‑Wave’s near‑term commercial viability based on those metrics.

On the technology side, D‑Wave’s potential is compelling—particularly after completing its acquisition of Quantum Circuits earlier in the year, which added a complementary technology stack and should help streamline system design and build.

Wall Street Analysts Remain Bullish, But Retail Investors May Not Have the Patience

Wall Street remains largely bullish: 14 of 16 ratings are a Buy or equivalent, and the consensus price target sits roughly 92% above current levels.

Retail investors, however, may be less willing to maintain a speculative position in a company that could still be some time away from aligning its financials with its technological promise.

Investors who can tolerate the volatility and believe management will grow revenue, rein in expenses, and differentiate D‑Wave’s quantum offerings from competitors may be early in backing a potential industry leader. That outcome is possible, but it’s far from guaranteed, and the timeline remains uncertain.

This email communication is a sponsored message sent on behalf of i2i Marketing Group, LLC, a third-party advertiser of MarketBeat. Why did I get this message?.

We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

If you have questions or concerns about your account, feel free to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place #620, Sioux Falls, South Dakota 57103. U.S.A..

🪙 Dividend Stocks Newsletter for 3/17/2026

Unsubscribe March 17, 2026 ALERT: Drop these 5 stocks before the market opens tomorrow! (ad)

The Wall Street Journal is asking whether a stock market crash is coming. Research from Weiss Ratings suggests the first half of 2026 could be very tough for certain stocks as a radical shift hits the market. Some of America’s most popular names could take serious damage. Analysts have identified five stocks you should consider avoiding before this event plays out. If these are in your portfolio, you’ll want to review your positions carefully.

See The Five Stocks To Avoid And Learn What’s Driving This Shift.Top Dividend NewsConflict Profits: Why These 2 Chemical Stocks Are Suddenly Soaring Assessing KE Holdings (NYSE:BEKE) Valuation After Weaker Earnings New Dividend And Completed Buybacks Geopolitics fade. This $150B trend won’t. (from Crypto 101 Media)Assessing Viper Energy (VNOM) Valuation As Its Royalty Model And Dividend Record Draw Fresh Attention Like Welltower? Check out this REIT stock that just hiked its dividend.Ares Management: Dividend Yield Spikes On 20% Hike And AI Ghosts, AUM Hits Record Wrapping Up Profits: Karat Packaging’s Earnings Reward OpenAI Could Go Public on March 18! (from The Oxford Club)Data Centers & Defense: 3 Soaring Stocks Boosting Dividends 3 Stocks That Could Be Next to Announce a Stock Split U.S. Shipbuilding Revival: 3 Stocks to Watch Now Ulta Beauty and an Ultimate Entry: Price Resets After Profit Miss

Dividend Stock Lists:

3 tickers just showed unusual early patterns. See the Trading Ideas report now. (ad)

Spot the Signals Before They Become Obvious

We track early shifts in volume, structure, and emerging trends as they begin to form.

Trading Ideas focuses on data patterns that often develop before broader visibility.

Join Free — Start Seeing The Data Early

Ex-Dividend Stocks for Wednesday, March 18th

CompanyShare PriceAmount / PeriodYieldPrevious AmountPayout RatioPayable DateAAONAAON$78.68$0.10
quarterly0.45%$0.1030.8%3/30/26
ARHSArhaus$7.43$0.35
special- – – 3/31/26
BPOPPopular$131.70$0.75
quarterly2.11%$0.7524.4%4/1/26
CSGSCSG Systems International$79.99$0.34
quarterly1.71%$0.3264.3%4/1/26
CURBCurbline Properties$26.94$0.17
quarterly2.46%$0.16168.4%4/8/26
DOLEDole$14.71$0.09
quarterly2.18%$0.0964.2%4/8/26
HBANHuntington Bancshares$15.33$0.16
quarterly3.51%$0.1644.6%4/1/26
IGICInternational General Insurance$24.61$1.15
annual4.60%- 7.0%4/6/26
KRPKimbell Royalty$14.70$0.37
quarterly10.21%$0.35225.8%3/25/26
KSSKohl’s$12.89$0.13
quarterly2.91%$0.1321.2%4/1/26
TUYATuya$2.41$0.06- – – 4/21/26
Please note you must purchase shares of these companies by the market close today to receive the next dividend payment.7 High-Yield Dividend Stocks You Need to See (ad)

7 High Yield Dividend Stocks to Buy Now 💰

Love steady payouts? This free report reveals 7 high-yield dividend stocks you need to know about. From Company #3, a tobacco giant innovating with smokeless products, to Company #4, famously known as “The Monthly Dividend Company,” these picks deliver steady income you can count on.

Perfect For Income-Focused Investors.

Ex-Dividend Stocks for Thursday, March 19th

CompanyShare PriceAmount / PeriodYieldPrevious AmountPayout RatioPayable DateGILGildan Activewear$59.15$0.25
quarterly1.44%$0.2334.4%4/13/26
IDTIDT$47.96$0.07
quarterly0.54%$0.068.6%3/31/26
KLICKulicke and Soffa Industries$65.79$0.21
quarterly1.31%$0.21-67.8%4/8/26
NDSNNordson$269.25$0.82
quarterly1.20%$0.8235.4%4/3/26
PMPhilip Morris International$175.82$1.47
quarterly3.49%$1.4780.9%4/13/26
QCRHQCR$82.29$0.10
quarterly0.44%$0.063.2%4/3/26
QSRRestaurant Brands International$75.21$0.65
quarterly3.92%$0.62105.1%4/2/26
SRESempra Energy$96.73$0.66
quarterly2.76%$0.6595.3%4/15/26
UWMCUWM$3.66$0.10
quarterly9.63%$0.10666.7%4/9/26
VICIVICI Properties$28.91$0.45
quarterly6.13%$0.4569.0%4/9/26
Please note you must purchase shares of these companies by the market close tomorrow to receive the next dividend payment.Why I’m avoiding Nvidia (and buying these 3 AI stocks instead) (ad)

Everyone’s buying Nvidia. The financial media can’t stop talking about it. Your neighbor probably owns it.

That’s exactly why I’m looking elsewhere.

See, when everyone piles into the same trade, the easy money is already gone. The real profits come from finding what the crowd is missing.

Click Here To Get Your Free Copy Of This Report

Ex-Dividend Stocks for Friday, March 20th

CompanyShare PriceAmount / PeriodYieldPrevious AmountPayout RatioPayable DateAINAlbany International$54.18$0.28
quarterly1.88%$0.28-55.4%4/7/26
ALNTAllient$62.96$0.03
quarterly0.20%$0.039.1%4/3/26
ASOAcademy Sports and Outdoors$50.50$0.15
quarterly1.00%$0.139.5%4/10/26
BMAMacro Bank$66.37$0.40
monthly6.44%$0.38145.9%3/27/26
CNQCanadian Natural Resources$48.71$0.63
quarterly5.57%$0.5945.5%4/7/26
HLNEHamilton Lane$101.62$0.54
quarterly1.59%$0.5438.8%4/6/26
IFFInternational Flavors & Fragrances$71.45$0.40
quarterly2.05%$0.40-116.8%4/10/26
INSWInternational Seaways$67.91$0.12
quarterly0.66%$0.127.7%3/30/26
MSIMotorola Solutions$468.03$1.21
quarterly1.03%$1.2137.9%4/15/26
NWGNatWest Group$15.60$0.627.43%- 27.9%5/5/26
PSOPearson$13.34$0.233.64%- – 5/15/26
RBCAARepublic Bancorp$69.06$0.50
quarterly2.64%$0.4526.8%4/17/26
SBSWSibanye Gold$13.31$0.26
annual1.64%- – 4/2/26
TNLTravel + Leisure$70.37$0.60
quarterly3.44%$0.5665.7%3/31/26
TPBTurning Point Brands$92.59$0.08
quarterly0.22%$0.089.6%4/10/26
VSTVistra$163.14$0.23
quarterly0.53%$0.2341.9%3/31/26
WHWyndham Hotels & Resorts$77.73$0.43
quarterly2.33%$0.4166.4%3/30/26
WMTWalmart$126.04$0.25
quarterly0.79%$0.2434.3%4/6/26
ZIMZIM Integrated Shipping Services$26.88$0.88
quarterly12.09%$0.311.5%3/26/26
Please note you must purchase shares of these companies by the market close tomorrow to receive the next dividend payment.

Dividend Stock Ideas

This is a list of companies that meet common criteria that investors use to evaluate dividend stocks. This list contains companies that have dividend yields greater than 3%, payout ratios of less than 75% (or less than 100% for REITs), five-year average annual dividend growth of at least 1.5% and a minimum market cap of $1 billion.CompanyDividend YieldAnnual PayoutPayout RatioAnnual Dividend GrowthP/E RatioMarket CapTBCGTBC Bank Group PLC9.32%GBX 886.6034.95%5.29%1.68£2.35KPRGOPerrigo Company plc11.93%$1.16N/A5.21%N/A$1.39KUKWGreencoat UK Wind PLC10.87%GBX 10.09N/A1.86%N/A£2.09KPKPark Hotels & Resorts Inc.9.52%$1.00N/A17.32%N/A$2.12KCAGConagra Brands8.73%$1.40N/A10.50%N/A$7.80KBMEB&M European Value Retail S.A.7.37%GBX 1560.73%2.73%7.27£1.80K

Dividend Research Tools:

Thank you for subscribing to DividendStocks.com’s daily newsletter!

DividendStocks.com provides a daily email newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news. DividendStocks.com is a subsidiary of MarketBeat Media, LLC and MarketBeat.com.

If you have questions or concerns about your account, don’t hesitate to contact MarketBeat’s U.S. based support team at contact@marketbeat.com.

Unsubscribe

Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, South Dakota 57103. USA..

Further Reading: ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings)

Bid on Burnes, Carroll, Gallen, and more!

Mar 17, 2026View OnlineGame-used bats, city connect jerseys, 2026 Spring Training baseballs and more! This new D-backs Authentics auction runs through 3/29 – place your bids now. To check your Watch List, access your Account, or update your info…
Log in to MLB Auctions
Don’t have an account?
Sign up here!© 2026 MLB Advanced Media, L.P. MLB trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com. Any other marks used herein are trademarks of their respective owners.

Please review our Privacy Policy.

You (pahovis@aol.com) received this message because you registered to receive commercial email messages from D-backs Auctions.

Please add dbacks@marketing.mlbemail.com to your address book to ensure our messages reach your inbox. If you no longer wish to receive commercial email messages from D-backs Auctions, please unsubscribe or log in and manage your email subscriptions.

Postal Address: D-backs Auctions, c/o MLB Advanced Media, L.P., 1271 Avenue of the Americas, New York, NY 10020.

The Rare Earth Fingerprint Tech – SMX

Unsubscribe

A message from SmallCaps Daily

SMX Emerges as a Critical Shield for U.S. National Security as Iran Conflict Threatens Rare Earth Flows

The strategic importance of rare earth minerals has skyrocketed amid the rising confrontation between the United States and Iran, as these materials underpin the technology, defense, and energy sectors that power national security.

Australia, a leading producer of rare earths, faces pressure to provide secure, verifiable, and compliant supply chains to meet U.S. demands. SMX (Security Matters) Public Limited (NASDAQ: SMX) offers a transformative solution: a molecular identity platform that embeds an indelible, verifiable signature into each mineral, enabling precise origin tracking from mine to market.

By converting supply chains into intelligent, self-verifying networks, SMXaddresses vulnerabilities that can otherwise be exploited during geopolitical instability, including counterfeiting, tampering, and unauthorized diversion of critical resources.

Operating from Singapore and leveraging Southeast Asia’s stable environment, SMX delivers a globally neutral, resilient, and scalable platform for supply-chain security.

Its technology not only verifies materials but strengthens regulatory compliance, industrial accountability, and defense readiness.

In times of conflict, such as the current Iran-U.S. tensions, this capability becomes indispensable: it ensures that essential rare earths are authenticated, traceable, and shielded from interference.

For governments, multinational enterprises, and defense partners, SMXrepresents more than innovation—it is a safeguard against uncertainty, a reinforcement of national security, and a commitment to transparency in a world where trust is fragile.

Discover why SMX is leading the charge in securing the world’s critical minerals

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Submitted by Nathan Reiff. Publication Date: 3/12/2026.

Key Points

Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Special Report: You’ve Got to See This Pattern Before 2025 Picks Up… (From Stock Wire News)

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with tailored mechanisms. Fortunately, a number of promising treatments have shown strong potential—and with that comes the possibility of significant sales.

Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond therapeutic promise, these drugs could help the firms move toward greater stability and, potentially, long-term profitability. That said, both remain high-risk investments: each faces clinical, regulatory, or commercial hurdles that could limit upside even as the rewards for success are substantial.

Iovance’s Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle

Stopping the Deadliest Animal on Earth (Ad)

Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.

Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.

With $6.4M in sales in just four years, they’re getting ready for the next step.Become a Med-X Shareholder Before Their Nasdaq Plans Unfold

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, jumping nearly 37% in a week when the S&P 500 slipped about 1%. That rally added to IOVA’s strong year-to-date performance, with shares more than doubling so far. Still, with a consensus price target of $8.88, Wall Street sees further upside—implying roughly 71% more gains from current levels.

The main catalyst behind Iovance’s move is its lead therapy, Amtagvi, a T‑cell immunotherapy for certain types of melanoma.

Amtagvi has been approved in the United States since 2024 and is building commercial momentum, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company’s IL‑2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak annual U.S. sales.

Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track designation for non‑small cell lung cancer and is being evaluated for other tumor types.

Some of Iovance’s outperformance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company posted narrower‑than‑expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year over year.

Iovance is still considered a small (about $2 billion) biotech, and despite the rally, analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are significant: in addition to typical small‑biotech concerns, Amtagvi is a personalized therapy that is costly and complex to manufacture. That manufacturing profile could constrain margins and profitability even as demand increases.

Massive Sales Growth for ImmunityBio’s Bladder Cancer Drug

Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year‑to‑date performance far outpaces Iovance’s. IBRX shares are up nearly 300% in 2026, and analysts remain optimistic: the consensus price target is $13.60, roughly 70% above the stock’s current level.

ImmunityBio’s primary growth driver is Anktiva, a treatment for certain forms of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—one of several recent approvals globally.

Anktiva is already material to the company’s top line: the drug generated $113 million in sales last year, a roughly 700% year‑over‑year increase.

Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional regulatory designations.

Despite the strong recent performance, IBRX remains speculative and risky.

The company reported a full‑year net loss of $351 million for 2025 as R&D and other expenses remain elevated. Analysts, however, are relatively bullish on ImmunityBio compared with Iovance: six out of seven covering the stock rate it a Buy or equivalent.

Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AMnewsletter that covers stories that will impact the stock market each day.

This email communication is a sponsored message provided by SmallCaps Daily, a third-party advertiser of The Early Bird and MarketBeat.

This message is a paid advertisement for SMX (NASDAQ: SMX) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $13,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding SMX (NASDAQ: SMX) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and SMX (NASDAQ: SMX).

If you need help with your subscription, feel free to contact our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from The Early Bird, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States..

Check This Out: [VIDEO] OpenAI IPO filing leaked – ticker revealed (delete after reading) (From The Oxford Club)

ZENA +10% Gains & Breaking News

*Read Disclaimer Sponsored Content

March 17, 2026 | Unsubscribe

Hello!

Following our alert this morning, ZENA opened today at 2.20, and so far, rallied to a high of 2.42, up +10% this morning.

ZENA is presenting another breakout opportunity – just as it has done multiple times in the past.

In addition, this morning the company released breaking news that could be an additional growth catalyst.

Here is the news from this morning:

“ZenaTech Develops Low-Cost, Single-Use Autonomous Interceptor Drone for ZenaDrone’s Counter-UAS System for US Defense, Middle East, and Ukraine Use”

“VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its ZenaDrone subsidiary has initiated development of a prototype for a small, one-way interceptor drone designed to stop hostile drones by physically intercepting them in flight. The prototype, called Interceptor-P1, is an autonomous and expendable vertical takeoff and landing (VTOL)-design drone that can be added to the company’s counter-UAS (Unmanned Aircraft System) defense system offering dramatically lower costs than traditional air munitions.”

“The drone addresses a critical asymmetry in modern warfare. Adversaries routinely deploy low-cost commercial and military drones at scale, while conventional intercept solutions, including surface-to-air missiles and laser systems, carry costs that are orders of magnitude higher than the threats they defeat. The Interceptor-P1 prototype is being purpose-built to reverse this equation.”

Here are some of the company’s comments from this press release:

“The drone threat on modern battlefields is accelerating faster than legacy defense budgets can absorb. Our Interceptor-P1 is being developed to give military and security forces an affordable, scalable answer by creating an interceptor and anti-drone system for a new world of asymmetric warfare,” said Shaun Passley, PhD, ZenaTech CEO. “Our strategy is to offer defense customers a full-spectrum of counter-drone solutions based on persistent maritime patrol with the ZenaDrone 2000 and IQ Glider launch station. Our emerging technologies are also forming a comprehensive, layered, counter-UAS ecosystem for land, sea, and littoral environments with the expendable point-intercept capabilities of the Interceptor P-1. This is exactly the kind of integrated, cost-effective capability that modern defense procurement demands.”

Furthermore:

“With versatile launch options planned, including ground, vehicle, and maritime deployment via the company’s IQ Glider, maritime drone platform, the Interceptor P-1 is being built to respond rapidly across multiple environments. By offering scalable interception capabilities, it is designed to help defense forces protect critical infrastructure, manage enemy drone swarms, and complement existing air defense systems as a strategic addition to ZenaDrone counter-UAS platform.”

“The company is targeting an initial prototype completion in the upcoming months and will provide further updates on product development, regulatory milestones, and defense and government agency engagement and pilots as progress continues.”

Here are a couple of the things to keep in mind as you are watching this opportunity.

Continue to watch for it to make higher lows and higher highs, that’s the first sign.

ZENA has a 20 day moving average of 2.51 – a breakout and close above this level could present increased upside potential.

ZENA has a 50 day moving average of 3.17, +44% from today’s open.

A close near the highs could be confirmation of upward momentum.

We are continuing to monitor ZENA for a sustainable breakout higher.

Sources: Presentation, PR, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, PR11, PR12, PR13, PR14, Website, Chart

Happy Trading!

SmallCapStocks Team

Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.

DISCLAIMER:

You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov; the Financial Industry Regulatory Authority (the “FINRA”) at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 3/13/26 for the distribution of this advertisement about ZENA dated 3/17/26. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 1/12/26 for the distribution of a prior advertisement about ZENA. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 12/9/25 for the distribution of a prior advertisement about ZENA. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at info@SmallCapStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:

http://www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Update your email preferences or unsubscribe here

1969 South Alafaya Trail
Orlando, Florida 32828, United StatesPowered by beehiiv Terms of Service

Dividend Stocks Keep Winning the Long Game

Your Daily Market Alert

LATEST NEWS

Why Boring Dividend Stocks Beat Chasing the Next Hot Thing

Every bull market creates its own cast of darlings. Right now, that’s artificial intelligence. Before that, we had meme stocks, SPACs, cannabis plays, and countless other….

LATEST NEWS

The S&P 500’s Growing Divide: Why Index Ownership Isn’t Enough Anymore

The S&P 500 has long represented a convenient shortcut for investors seeking exposure to America’s corporate elite. Own the index, the thinking goes, and you’ll capture….

SPONSORED

Trump’s Crypto Law Just Created a Massive Opportunity

See the #1 Coin Riding Trump’s Crypto Revolution

LATEST NEWS

AMD Deserves a Closer Look in the AI Hardware Race

The AI semiconductor story has become almost synonymous with one name, but that narrative oversimplifies a rapidly evolving competitive landscape. Nvidia’s dominance….

SPONSORED

The 5-Minute Daily Read That Beats the Markets

Miss this and you could miss tomorrow’s best moves. The American Market Brief delivers early insights on sectors, stocks, and market strategies. It’s free, fast, and clear.

Get Your First Brief Tomorrow

LATEST NEWS

Bitcoin’s Path Back to $100,000 Lies in Gold’s Shadow

Bitcoin’s recent tumble back to around $70,000 might look like déjà vu to anyone who lived through 2024. After touching $126,000 last year, the world’s largest…

SPONSORED

Invest Like America’s Future Depends On It

Wall Street forgot Main Street. We didn’t. Get daily insights on U.S. stocks, policy shifts, and sectors powering the American economy. Join over 15,000 investors already taking advantage of our analysis.

Start Your Free Subscription Now

SPONSORED

Trump’s Crypto Law Just Created a Massive Opportunity

(Privacy Policy/Disclosures)

See the Coin Crypto Billionaires Are Quietly Buying →

(Privacy Policy/Disclosures)

Click here to request your copy now

2026 Dividend Watchlist (Just Released)

(Privacy Policy/Disclosures)Advertising Disclosure: This email contains paid advertisements. This email is from our associates at Investment News Daily.

Legal Entity Information: Investing Ideas Daily is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc.

Unsubscribe: You are receiving this email as part of your complimentary subscription to the Investing Ideas Daily E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below.Darwin Investor Network
2319 N Andrews Avenue, Fort Lauderdale, FL 33311
support@investingideasdaily.com | 1-800-496-9838Investing Ideas Daily | Privacy Policy | Terms of Use
Unsubscribe | View Online